小剂量利妥昔单抗治疗原发免疫性血小板减少症的疗效观察  

Efficacy of low-dose rituximab for patients with immune thrombocytopenia

作　　者：张玲[1] 龙冰[1] 李旭东[1] 方志刚[1] 曾芸馨[1] 林东军[1] 

机构地区：[1]中山大学附属第三医院血液科,广东广州510630

出　　处：《热带医学杂志》2015年第6期800-802,共3页Journal of Tropical Medicine

摘　　要：目的探讨小剂量利妥昔单抗治疗原发免疫性血小板减少症(ITP)的疗效及安全性。方法本研究对11例ITP患者采用小剂量利妥昔单抗治疗,100 mg/周静脉滴注,连用4周,每周监测患者血常规、肝肾功能和凝血功能。监测治疗前后血清免疫球蛋白(Ig G、Ig M、Ig A)和补体(C3、C4)水平。结果治疗后血小板计数明显高于治疗前,差异有统计学意义(P<0.01)。11例患者中完全有效(CR)6例,有效(R)3例,无效(NR)2例,总有效率为81.82%。治疗前后患者外周血白细胞数、血红蛋白、血清Ig G、Ig M、Ig A、C3、C4水平差异无统计学意义。1例继发肺部感染。结论小剂量利妥昔单抗用于治疗ITP患者,具有良好的疗效。Objective To explore the efficacy and safety of low-dose rituximab for patients with immune thrombocytopenia.Methods 11 patients were treated with low-dose rituximab, 100 mg weekly for 4 consecutive weeks. Blood cell count,liver and kidney functions and blood coagulation were monitored weekly. Serum concentrations of Ig G, Ig M, Ig A, C3 and C4 were observed before and after therapy. Results There was significant difference of platelet count between untreated and treated group（P〈0.01）. In 11 patients, 6 cases of complete response（CR）, 3 cases of response（R） and2 cases of no response（NR）; the overall effective rate was 81.82%. There were no differences of peripheral blood white blood cell counts, hemoglobin, serum Ig G, Ig M, Ig A, C3 and C4 levels before and after therapy. 1 patient developed pulmonary infection. Conclusion Low-dose rituximab is effective treatment for patients with immune thrombocytopenia.

关 键 词：利妥昔单抗 小剂量 免疫性血小板减少症 疗效 

分 类 号：R558.2[医药卫生—血液循环系统疾病]